Supplemental material
Report
Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies
, 
, , , , , , , , & show all
Cindy ZhangGenentech Research & Early Development, Genentech, Inc, South San Francisco, CA, USAhttps://orcid.org/0000-0002-0243-7842View further author information
https://orcid.org/0000-0002-0243-7842View further author information, , Divya SamineniGenentech Research & Early Development, Genentech, Inc, South San Francisco, CA, USAhttps://orcid.org/0000-0001-6300-2044View further author information
https://orcid.org/0000-0001-6300-2044View further author information, Dan LuGenentech Research & Early Development, Genentech, Inc, South San Francisco, CA, USAhttps://orcid.org/0000-0003-4718-3564View further author information
https://orcid.org/0000-0003-4718-3564View further author information, , Shang-Chiung ChenGenentech Research & Early Development, Genentech, Inc, South San Francisco, CA, USAhttps://orcid.org/0000-0002-0754-3716View further author information
https://orcid.org/0000-0002-0754-3716View further author information, Rong ZhangGenentech Research & Early Development, Genentech, Inc, South San Francisco, CA, USAhttps://orcid.org/0000-0001-5107-1974View further author information
https://orcid.org/0000-0001-5107-1974View further author information, , & show allRelated Research Data
Population pharmacokinetics of therapeutic monoclonal antibodies.
Source:
Springer Science and Business Media LLC
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Source:
American Association for Cancer Research (AACR)
Pharmacokinetic considerations for antibody drug conjugates.
Source:
Springer Science and Business Media LLC
A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
Source:
Springer Science and Business Media LLC
Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.
Source:
Elsevier BV
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Source:
Springer Science and Business Media LLC
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
Source:
Springer Nature
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.
Source:
Future Science Ltd
Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics
Source:
Springer Science and Business Media LLC
Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.
Source:
Future Science Ltd
Antibody Drug Conjugates as Cancer Therapeutics
Source:
MDPI AG
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index.
Source:
Springer Science and Business Media LLC
Clinical pharmacology and assay consideration for characterizing pharmacokinetics and understanding efficacy and safety of antibody–drug conjugates
Source:
Future Science Ltd
Linking provided by
